Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Effect of Hydrogen-rich Water During Tapering on Recovery After Functional Overreaching in Basketball Players

15 luglio 2026 aggiornato da: Jakub Krejci, Palacky University

Effect of Hydrogen-rich Water Supplementation During Tapering on Recovery After Functional Overreaching in Competitive Male Basketball Players: A Randomized, Double-blind, Placebo-controlled Paralel-group Trial

The goal of this clinical trial is to evaluate whether hydrogen-rich water supplementation during tapering improves recovery after functional overreaching in competitive male basketball players aged 18-35 years. The main questions it aims to answer are:

  • Does hydrogen-rich water improve autonomic recovery after functional overreaching?
  • Does hydrogen-rich water improve recovery in biochemical, performance, and subjective feeling outcomes during tapering?

Researchers will compare hydrogen-rich water to placebo (water containing no molecular hydrogen) to determine whether molecular hydrogen improves recovery after accumulated fatigue has been induced by functional overreaching. Participants will:

  • Complete a training cycle including normal training, functional overreaching, and tapering.
  • Consume hydrogen-rich or placebo water daily during the one-week tapering period.
  • Undergo repeated testing of autonomic nervous system, blood biochemical markers, performance, and subjective soreness.

Panoramica dello studio

Stato

Non ancora reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

The study consists of an initial screening and entry testing phase, followed by one week of normal training, two weeks of functional overreaching, and one week of tapering. During the functional overreaching period, training load is increased to approximately 120-130% of normal training load to induce accumulated fatigue. During the tapering period, training volume is reduced to approximately 50-60% of normal training volume to support recovery and performance rebound.

The molecular hydrogen is administered only during the tapering period. Participants in the experimental group consume 2.5 L per day of hydrogen-rich water. The total daily dose is divided into 0.5 L in the morning, 1.5 L around training, and 0.5 L in the evening. Participants in the placebo group consume visually matched placebo water according to the same total daily intake and timing schedule. Supplementation adherence is monitored using logs, dose counts, and attendance records. Participants are randomly assigned in a 1:1 ratio to either the experimental group or the placebo group. Randomization is performed using a block scheme and a computer random number generator.

Testing is performed at multiple time points: entry laboratory testing, baseline after normal training, post-functional overreaching, and post-taper. The primary interval for evaluation is the change from post-functional overreaching to post-taper. Statistical analysis is based on a t-test or analysis of variance. Data that not follow a normal distribution are treated using a logarithmic transformation or analyzed using nonparametric tests. The significance level is set at 0.05.

Tipo di studio

Interventistico

Iscrizione (Stimato)

30

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

Luoghi di studio

  • Cechia
      • Olomouc, Cechia, 77111
        • Palacky University, Faculty of Physical Culture
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Adulto

Accetta volontari sani

Sì

Descrizione

Inclusion Criteria:

  • Competitive male basketball players.
  • Signed informed consent.
  • Completion of entry medical and laboratory screening.

Exclusion Criteria:

  • Acute injury or infection.
  • History or presence of relevant cardiovascular, respiratory, metabolic, or other disease that may affect the study results.
  • Use of medication affecting recovery markers or study results.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Scienza basilare
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Doppio

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Hydrogen-rich water
Hydrogen-rich water administered at a dose of 2.5 L per day during a one-week tapering period.
Integratore alimentare: Hydrogen-rich water
Hydrogen-rich water with molecular hydrogen concentration >1.0 ppm.
Altri nomi:
  • Tirtan generator (Nutristamina, Ostrava, Czech Republic)
Comparatore placebo: Placebo water
Placebo water administered at a dose of 2.5 L per day during a one-week tapering period.
Integratore alimentare: Placebo water
Tap water without molecular hydrogen.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
RMSSD
Lasso di tempo: One-week change between post-overreaching and post-taper.
The root mean square of successive differences of RR intervals (RMSSD) is used as an index of parasympathetic activity and is calculated from an ECG using heart rate variability analysis.
One-week change between post-overreaching and post-taper.

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Creatine kinase
Lasso di tempo: One-week change between post-overreaching and post-taper.
Blood creatine kinase concentration is used as a marker of muscle damage.
One-week change between post-overreaching and post-taper.
High-sensitivity C-reactive protein
Lasso di tempo: One-week change between post-overreaching and post-taper.
High-sensitivity C-reactive protein concentration is used as a marker of systemic inflammatory.
One-week change between post-overreaching and post-taper.
Cortisol
Lasso di tempo: One-week change between post-overreaching and post-taper.
Blood cortisol concentration is used as a marker of physiological stress response.
One-week change between post-overreaching and post-taper.
Testosterone
Lasso di tempo: One-week change between post-overreaching and post-taper.
Blood testosterone concentration is used as a marker related to anabolic-catabolic balance.
One-week change between post-overreaching and post-taper.
Urea
Lasso di tempo: One-week change between post-overreaching and post-taper.
Blood urea concentration is used as a marker related to metabolic and protein-turnover stress.
One-week change between post-overreaching and post-taper.
Leukocytes
Lasso di tempo: One-week change between post-overreaching and post-taper.
Blood leukocyte count is used as a marker of immune-related response to training.
One-week change between post-overreaching and post-taper.
Lymphocytes
Lasso di tempo: One-week change between post-overreaching and post-taper.
Blood lymphocyte count is used as a marker of immune-related response to training.
One-week change between post-overreaching and post-taper.
Neutrophils
Lasso di tempo: One-week change between post-overreaching and post-taper.
Blood lymphocyte count is used as a marker of imflammatory response to training.
One-week change between post-overreaching and post-taper.
Reactive strength index
Lasso di tempo: One-week change between post-overreaching and post-taper.
Reactive strength index is used as an marker of neuromuscular function of the lower limbs and is measured using a drop jump.
One-week change between post-overreaching and post-taper.
Hangrip test
Lasso di tempo: One-week change between post-overreaching and post-taper.
Handgrip test is used as a marker of forearm muscle strength and is measured using a dynamometer.
One-week change between post-overreaching and post-taper.
20-m sprint
Lasso di tempo: One-week change between post-overreaching and post-taper.
20-m sprint test is used to assess linear speed.
One-week change between post-overreaching and post-taper.
Repeated sprint
Lasso di tempo: One-week change between post-overreaching and post-taper.
20 x 15 m repeated sprint test is used to asses repeated sprint ability.
One-week change between post-overreaching and post-taper.
Agility T-test
Lasso di tempo: One-week change between post-overreaching and post-taper.
Agility T-test is used to assess planned change-of-direction performance.
One-week change between post-overreaching and post-taper.
Basketball jump shot accuracy test
Lasso di tempo: One-week change between post-overreaching and post-taper.
Basketball jump shot accuracy test is used to assess basketball-specific performance.
One-week change between post-overreaching and post-taper.
Muscle soreness
Lasso di tempo: One-week change between post-overreaching and post-taper.
Muscle soreness is assessed subjectively using a visual analog scale, which is represented by a 100 mm line marked 0 (no pain) and 100 (worst imaginable pain).
One-week change between post-overreaching and post-taper.

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Palacky University

Investigatori

  • Investigatore principale: Jan Kvas, Palacky University

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

1 agosto 2026

Completamento primario (Stimato)

1 dicembre 2026

Completamento dello studio (Stimato)

1 dicembre 2026

Date di iscrizione allo studio

Primo inviato

15 luglio 2026

Primo inviato che soddisfa i criteri di controllo qualità

15 luglio 2026

Primo Inserito (Effettivo)

20 luglio 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

20 luglio 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

15 luglio 2026

Ultimo verificato

1 luglio 2026

Maggiori informazioni

Termini relativi a questo studio

Parole chiave

Altri numeri di identificazione dello studio

  • FTK_2026_13

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

All IPD that underlie results in a publication.

Periodo di condivisione IPD

Beginning 1 month after the publication of results with no end date.

Criteri di accesso alla condivisione IPD

Anonymized IPD will be uploaded to an open-access data repository.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Prove cliniche su Hydrogen-rich water

Cerca prove simili

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

CROs by country

CROs in Burundi

Condizioni

Malattie rare

Interventi farmacologici

Supplementi dietetici

Sponsor / Collaboratori

Sedi

Sottoscrivi